Oramed Pharmaceuticals Inc (ORMP) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the technical indicators show some bullish momentum, the company's financial performance is weak, and there are no significant positive catalysts to justify immediate investment. Given the lack of strong trading signals and the recent reverse stock split, it is prudent to hold off on investing until more favorable conditions or stronger growth signals emerge.

Technical Analysis

The technical indicators show a mixed picture. The MACD is slightly positive at 0.0179, indicating mild bullish momentum, and the RSI is neutral at 52.82. Moving averages are bullish with SMA_5 > SMA_20 > SMA_200, suggesting an upward trend. Key support and resistance levels are Pivot: 3.405, R1: 3.645, S1: 3.164, R2: 3.794, S2: 3.015.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

The partnership with Lifeward to integrate oral delivery technology could potentially unlock up to $47 million in capital for growth initiatives.

Neutral/Negative Catalysts

The company recently underwent a 1-for-12 reverse stock split, its second since 2024, which may indicate ongoing financial struggles. Additionally, the board's decision to increase authorized share capital amidst a 20% stock value drop raises concerns about dilution.

Financial Performance

In Q3 2025, the company reported a 0% YoY revenue growth, a net income drop of -346.67% YoY, and a significant EPS decline of -335.42% YoY. Gross margin remained flat at 0.65.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

Analyst Rating

Wall Street analysts forecast ORMP stock price to rise

Buy

Hold

Sell

Current: 3.340

Low

Averages

High